Millions of people around the world now take a weekly injection to lose weight or control their blood sugar. This week, the US Food and Drug Administration (FDA) told the makers of the best-known GLP-1 drugs that their labels must carry a new warning: a rare eye condition that can lead to sudden, permanent loss of vision in one eye.
The order covers Ozempic, Wegovy, Mounjaro and Zepbound, the medicines that have turned GLP-1 treatments into one of the biggest stories in modern pharmaceuticals. The condition in question has a long name, nonarteritic anterior ischemic optic neuropathy, usually shortened to NAION. It is not a new disease, but the regulator now says the evidence is strong enough that patients and doctors should be told about it in black and white.
NAION happens when the small blood vessels that supply the optic nerve become blocked. Deprived of oxygen, the nerve that carries images from the eye to the brain is damaged. According to the FDA, the result is typically a painless decrease in vision in one eye, and that loss can be permanent. There is no known treatment that reverses vision loss caused by NAION. The American Academy of Ophthalmology describes it as the most common cause of acute optic nerve injury in people over 50.
The FDA said it based its decision on a detailed review of NAION reports among GLP-1 users, together with other published studies. Its conclusion is carefully worded: there is an “increased risk of rare NAION events” in people taking these drugs. What the regulator does not yet know is why. It also acknowledged a major complication in the research: many people who take GLP-1 medicines for obesity or type 2 diabetes already carry risk factors for NAION, such as problems with blood vessels and circulation, regardless of the drug.
That nuance is why the reaction from doctors has been measured rather than alarmed. In a statement, the American Academy of Ophthalmology said that “any added risk appears small, and it has not been established that these medications cause NAION.” The academy stressed that GLP-1 medicines offer important benefits for people with diabetes, obesity and heart disease, and gave patients a simple two-part message: do not stop your medication without talking to your doctor, and if you notice sudden, painless vision loss in one eye, see an ophthalmologist promptly.
Novo Nordisk, which makes Ozempic and Wegovy, also pushed back on the idea of a proven link. The company said it believes the data “do not establish a cause-and-effect relationship”, while adding that NAION “can have a profound impact on patients and their families” and that patient safety remains a top priority. Novo said it would continue to monitor the safety of its medicines.
What the research says so far
The question of GLP-1 drugs and eye health has been building for several years. Two years ago, US researchers published a study analysing around 17,000 patients and found that those taking semaglutide, the active ingredient in Ozempic and Wegovy, were four times more likely to be diagnosed with NAION than people who were not on the drug. The figure made headlines, but one of the study’s authors, Harvard Medical School ophthalmology professor Dr Joseph Rizzo, described the findings as “significant but tentative”. He called for more research, especially in a more diverse group of patients, before firm conclusions are drawn.
European regulators have also looked at the issue. Last year, a safety committee of the European Medicines Agency said that NAION may affect up to 1 in 10,000 people taking semaglutide. That places it firmly in the category of very rare side effects, but with GLP-1 prescriptions running into the millions, even a very rare event can affect a meaningful number of people in absolute terms.
The new US warning therefore does two things at once. It does not say the drugs are unsafe, and it does not tell anyone to stop treatment. But it formally recognises that the signal seen in studies and case reports is real enough to belong on the label, which is where doctors and patients look when they weigh benefits against risks.
The GLP-1 labels already list several other possible problems. They carry warnings about pancreatitis and gallbladder disease, and the most common side effects of semaglutide are well known to anyone who has taken it: nausea, vomiting and stomach pain. NAION now joins that list as a rare but potentially serious item.
For patients, the practical advice is straightforward. Vision changes that come on suddenly, especially in one eye and without pain, should never be brushed aside as tiredness or screen strain. Because NAION is painless, people sometimes notice it only when they wake up and find part of their field of vision dim or blurred. Prompt examination by an eye specialist matters, both to confirm the diagnosis and to rule out other causes that can be treated.
Doctors, meanwhile, are likely to pay closer attention to patients who already have several risk factors for optic nerve problems. That could include a closer look at eye health before treatment begins, and a clear conversation about what symptoms to watch for. For many patients with severe obesity, diabetes or heart disease, the benefits of GLP-1 therapy are substantial, from better blood sugar control to weight loss and lower cardiovascular risk. The new label is meant to make that trade-off more transparent, not to tip it automatically one way or the other.
The decision also reflects how quickly these medicines have moved from niche diabetes drugs to mass-market treatments. As more people take them for longer periods, regulators gain far more data than was available in the original clinical trials, and rare side effects that were invisible in a few thousand trial participants can become measurable in millions of real-world users. Label updates such as this one are a normal part of that process.
What remains open is the biological question at the heart of the warning. Researchers still need to explain whether GLP-1 drugs themselves affect blood flow to the optic nerve, whether rapid changes in blood sugar or weight play a role, or whether the link mostly reflects the underlying health of the people who take them. Until those answers arrive, the message from regulators and eye doctors is the same: the risk is small, but it is real enough to know about, and sudden vision loss in one eye is always a reason to see a specialist without delay.





